The strong U.S. launch trajectory for IMCIVREE in acquired HO and positive RM-718 data support a re-rating of the commercial opportunity. Monitor upcoming catalysts: Japan MHLW decision on IMCIVREE for HO by year-end 2026, Phase 3 bivamelagon trial initiation, and RM-718 Part D enrollment completion. The narrowed OpEx guidance provides cost visibility.
Price Chart
Executive Summary
Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.73 (vs -$0.83 consensus, a 12.0% beat), driven by a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO). The company also announced positive preliminary Phase 2 data for its weekly injectable MC4R agonist RM-718, showing an -11.6% mean BMI reduction at 16 weeks, and narrowed its 2026 Non-GAAP OpEx guidance to $363M-$397M (from $385M-$415M). The combination of a top- and bottom-line beat, accelerating U.S. revenue growth (+38% QoQ), and encouraging pipeline data is a clear positive signal for the commercial story and long-term growth trajectory.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $71.3M vs consensus $67.7M (+5.3% beat)
- GAAP EPS -$0.73 vs consensus -$0.83 (+12.0% beat)
- U.S. IMCIVREE revenue $51.0M, up 38% QoQ from Q1 2026
- Over 400 patient start forms for IMCIVREE in acquired HO since FDA approval
- RM-718 Phase 1/2 data: -11.6% mean BMI reduction at 16 weeks in acquired HO (n=7)
- 2026 Non-GAAP OpEx guidance narrowed to $363M-$397M from $385M-$415M
- Cash position $330.9M, sufficient for at least 24 months
Financial Impact
Revenue beat of $3.6M (+5.3%) and EPS beat of $0.10 (+12.0%) vs consensus; U.S. revenue growth of $14.1M (+38%) QoQ
Risk Factors
- Ex-U.S. revenue declined 13% QoQ due to a $3.8M retrospective charge in France
- Net loss widened to $50.4M in Q2 2026 from $48.0M in Q2 2025
- SG&A expenses rose 47% YoY to $67.4M, outpacing revenue growth
- Dependence on acquired HO launch for near-term growth; competitive risk from other MC4R agonists
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3338168 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 144 | $96.77 $99.27 | ▼ −2.58% | ▼ −0.47% | $93.68 (+3.19%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▲ +1.65% | ▲ +1.45% | $93.68 (+18.72%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▼ −1.65% | ▼ −1.45% | $93.68 (−18.72%) |
Aug 4, 2026 8w ago | 8-K | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Aug 4, 2026 8w ago | Press Release | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Jul 8, 2026 12w ago | Press Release | $115.48 $106.09 | ▼ −8.13% | ▼ −8.00% | $93.68 (−18.88%) |
Jun 22, 2026 14w ago | 144 | $106.19 $110.04 | ▲ +3.63% | ▲ +2.61% | $93.68 (−11.78%) |
Jun 15, 2026 15w ago | 8-K | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 15, 2026 15w ago | Press Release | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 13, 2026 15w ago | Press Release | $89.70 $101.39 | ▲ +13.03% | ▲ +14.42% | $93.68 (+4.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access